The early acquisition of a KRAS mutation is likely essential for triggering the adenoma-carcinoma sequence in pancreatic tumors12, and molecular profiling of KRAS and GNAS can help with determining whether invasive cancer in a pancreas with an IPMN is associated or concomitant13. The gene discussed is KRAS; the disease is pancreatic intraductal papillary-mucinous neoplasm.